Rifaximin

Generic Name
Rifaximin
Brand Names
Xifaxan, Zaxine
Drug Type
Small Molecule
Chemical Formula
C43H51N3O11
CAS Number
80621-81-4
Unique Ingredient Identifier
L36O5T016N
Background

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...

Indication

Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...

Associated Conditions
Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
Associated Therapies
-
Clinical Trials
Related News

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

First Posted Date
2018-10-19
Last Posted Date
2021-07-20
Lead Sponsor
Mallinckrodt
Target Recruit Count
50
Registration Number
NCT03712280
Locations
🇺🇸

Global Clinical Professionals, Saint Petersburg, Florida, United States

🇺🇸

Inland Empire Clinical Trials, Rialto, California, United States

🇺🇸

Southern California Research Center, Coronado, California, United States

and more 2 locations

The Effect of Rifaximin on Portal Vein Thrombosis

Not Applicable
Conditions
Portal Vein Thrombosis
Cirrhosis
Interventions
Drug: Rifaximin
First Posted Date
2018-08-15
Last Posted Date
2018-08-15
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
96
Registration Number
NCT03631147
Locations
🇨🇳

180 Fenglin Road, Shanghai, Shanghai, China

Microbiota Intervention to Change the Response of Parkinson's Disease

Phase 1
Suspended
Conditions
Parkinson Disease
Interventions
Other: Placebo
Drug: Rifaximin
First Posted Date
2018-07-02
Last Posted Date
2024-06-26
Lead Sponsor
University of California, San Francisco
Target Recruit Count
86
Registration Number
NCT03575195
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

Early Phase 1
Completed
Conditions
Microbial Colonization
Interventions
Drug: Rifaximin
First Posted Date
2018-05-18
Last Posted Date
2021-10-12
Lead Sponsor
Emory University
Target Recruit Count
26
Registration Number
NCT03529825
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Rifaximin on Visceral Hypersensitivity

First Posted Date
2018-03-13
Last Posted Date
2022-09-13
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
4
Registration Number
NCT03462966
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease

First Posted Date
2017-06-14
Last Posted Date
2017-06-14
Lead Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Target Recruit Count
120
Registration Number
NCT03185611
Locations
🇨🇳

The Sixth Affiliated Hospital, Sun Yat-sen University, Guanzhou, Guangdong, China

Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease

Phase 3
Conditions
Crohn Disease
Interventions
Drug: Rifaximin
First Posted Date
2017-06-14
Last Posted Date
2017-07-19
Lead Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Target Recruit Count
80
Registration Number
NCT03185624
Locations
🇨🇳

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

First Posted Date
2017-04-21
Last Posted Date
2018-03-22
Lead Sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Target Recruit Count
40
Registration Number
NCT03124199
Locations
🇪🇸

Hospital Universitario de La Princesa, Madrid, Spain

High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.

First Posted Date
2017-04-14
Last Posted Date
2019-11-04
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Registration Number
NCT03115697
Locations
🇮🇳

Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Phase 4
Completed
Conditions
Covert Hepatic Encephalopathy
Interventions
Drug: Rifaximin
First Posted Date
2017-03-10
Last Posted Date
2021-07-01
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
40
Registration Number
NCT03077217
Locations
🇨🇳

Shanghai changzheng Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy